explore -WSS

explore

author：Wikipedia 2025-10-01 21:35:04 - browse：5552

Illumina said Monday afternoon that its board of directors had approved a spin-off of its cancer test subsidiary Grail, signaling that a nearly four-year-long, $8 billion saga will finally draw to a close this month.

Shares in the newly independent Grail are expected to be distributed on June 24, Illumina said in a statement. Illumina will retain a 14.5% stake in the company, which will trade under the ticker $GRAL.

It’s the second time Illumina has spun off Grail, which initially began as a unit within the DNA sequencing giant in 2015. Illumina turned it into an independent company the following year but then agreed to reacquire it for $8 billion in September 2020.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Readout Newsletter: Bluebird, CVS, Contineum

Wikipedia

WSS

Biotech venture capitalists face new demands from investors

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

The surgeon had a dilemma only a Nazi medical text could resolve

Readout Newsletter: Merck, J&J, and long Covid

Future doctors should be trained to promote social change

eGenesis tests gene

hotspot

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Supreme Court strikes down use of affirmative action

Methadone treatment changes are coming. Do they go far enough?

Moonlake's readout produced a cash windfall. Risks remain

SCOTUS questions limit to govt efforts to fight misinformation

State Dept. review finds Biden bears some blame for Afghanistan failures

Orchard's therapy for neuron disease in children wins FDA approval

After affirmative action ruling, medical educators look to 'holistic review'

U.K. researchers warn about biases in medical devices, algorithms

In Memoriam: Notable people who died in 2023

New brain studies show LSD's effects on the brain in full color

leisure time

Think you might have Covid

NIH director takes cautious approach to Biden drug pricing priority

Stop the failed accountable care organization experiment

Leading voice in opioid treatment defends methadone clinic system

Eli Lilly, Pfizer, and others want in on the online prescription market

Humana cuts profit projections as Medicare Advantage costs soar

Wikipedia

entertainment

Wikipedia

focus